TECHNELITE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNELITE (TECHNELITE).
Technetium Tc-99m generator; Tc-99m decays by isomeric transition emitting gamma rays, allowing imaging. As a radiotracer, it localizes in various tissues depending on the labeled compound.
| Metabolism | Not metabolized; Tc-99m decays physically with a half-life of 6.01 hours to Tc-99. |
| Excretion | Primarily renal (90-95% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for <5%. |
| Half-life | 6.0 hours (terminal elimination half-life in adults with normal renal function); clinically, dosing interval adjustment is necessary in renal impairment. |
| Protein binding | Low (<5%); weakly bound to albumin. |
| Volume of Distribution | 0.35 L/kg; indicates confinement primarily to extracellular fluid. |
| Bioavailability | Intravenous: 100%; oral: not applicable (undergoes first-pass metabolism and is not administered orally). |
| Onset of Action | Intravenous: immediate (within minutes) as bolus for imaging; oral: not applicable (diagnostic use only). |
| Duration of Action | Sufficient for diagnostic imaging (typically 1-2 hours post-injection); renal clearance limits prolonged exposure. |
Intravenous administration of 1-30 mCi (37-1110 MBq) as a single dose for imaging procedures; dose adjusted based on patient weight and imaging protocol.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment as technetium-99m pertechnetate is eliminated by both renal and extrarenal routes; however, in severe renal impairment (GFR <15 mL/min), consider reducing dose by 50% to minimize radiation exposure. |
| Liver impairment | No specific dose adjustment recommended for hepatic impairment; monitor for altered biodistribution but no Child-Pugh based modifications established. |
| Pediatric use | Weight-based dosing: 0.1-0.2 mCi/kg (3.7-7.4 MBq/kg) intravenously, minimum dose 0.5 mCi (18.5 MBq), maximum dose per pediatric protocol not to exceed 20 mCi (740 MBq); adjust based on imaging indication. |
| Geriatric use | Dose should be selected cautiously, starting at the lower end of the dosing range (1-10 mCi or 37-370 MBq) due to potential decreased renal function and increased sensitivity to radiation; monitor for image quality. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNELITE (TECHNELITE).
| Breastfeeding | Technetium-99m is excreted into breast milk. The M/P ratio is approximately 1.0. The American College of Radiology recommends interrupting breastfeeding for at least 24 hours after administration. For longer-lived contaminants (e.g., Tc-99 contamination), longer interruption may be needed. |
| Teratogenic Risk | Technelite (technetium Tc-99m generator) is a radiopharmaceutical. The radioactive decay emits gamma radiation which can cause fetal harm. Risk is dose-dependent. In the first trimester, high doses may cause spontaneous abortion or major malformations. In the second and third trimesters, risks include growth restriction, microcephaly, and intellectual disability. The teratogenic risk is highest with exposures >500 mGy. For diagnostic doses, the risk is low, but use only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to technetium or any component of the preparation."]
| Precautions | ["Risk of radiation exposure; use only when diagnostic benefit outweighs risk.","Allergic reactions possible.","Pregnancy and breastfeeding: caution.","Ensure proper hydration to minimize radiation exposure to bladder."] |
Loading safety data…
| Fetal Monitoring | Monitor fetal position and placental location prior to administration if possible. Use the lowest possible dose. Administer only when potential benefit justifies risk. Consider use of nuclear medicine imaging alternatives with less radiation exposure (e.g., MRI). |
| Fertility Effects | Radioactive iodine isotopes (if present as contaminants) may concentrate in gonads and cause temporary or permanent infertility at high doses. With diagnostic use, gonadal doses are typically low (<10 mGy), and no significant effect on fertility is expected. However, caution is advised. |